Morrison & Foerster LLP advised Krystal Biotech, Inc. on its initial public offering of 4,554,000 shares of common stock at a price of $10.00 per share, which includes 594,000 shares of common stock exercised pursuant to the underwriter’s over-allotment option. Aggregate gross proceeds to the company were $45,540,000, before underwriting discounts, commissions and expenses. The stock is listed on the NASDAQ Capital Market (NASDAQ) under the symbol “KRYS”. The offering closed on September 22, 2017.
Founded in San Francisco and based in Pittsburgh, PA, Krystal Biotech is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases.
The MoFo team advising Krystal is led by San Francisco-based corporate partner John Campbell and includes corporate associates Emiko Kurotsu (Palo Alto) and Katherine Shaia (Washington, D.C.).
Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering.
See the related press release.
Select media coverage: